Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

Summary

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Timeline

Start

2026-02-13

Primary completion

2027-09

Completion

2027-09

Drugs

Indications